Related Experiment Video
Updated: Jul 14, 2026
06:51
Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay
Published on: July 21, 2021
Hsp90 inhibitors in the clinic.
1Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey.
Handbook of Experimental Pharmacology
|April 14, 2006
Summary
Heat shock protein 90 (Hsp90) inhibitors are advancing in clinical trials for metastatic cancers. These agents show promise by blocking multiple cancer pathways, with manageable toxicity and early signs of activity.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Heat shock protein 90 (Hsp90) is crucial for stabilizing proteins involved in cancer cell growth and survival.
- Dysregulation of protein folding is implicated in various diseases, including cancer.
- Hsp90 inhibitors offer a novel therapeutic strategy by simultaneously targeting multiple oncogenic pathways.
Purpose of the Study:
- To provide an update on current clinical trials involving Hsp90 inhibitors.
- To highlight the potential of Hsp90 inhibitors in treating metastatic cancers and other diseases.
- To discuss the future relevance of Hsp90 inhibitors in clinical practice over the next five years.
Main Methods:
- Review of ongoing and completed Phase I and Phase II clinical trials of Hsp90 inhibitors.
- Analysis of efficacy and toxicity data from these trials.
- Assessment of the rationale for Hsp90 inhibitor use in diseases beyond cancer.
Main Results:
- The first Hsp90 inhibitor, 17-AAG, has completed Phase I and is in Phase II trials.
- Manageable toxicity profiles have been observed.
- Evidence of clinical activity has been noted in metastatic melanoma, prostate cancer, and multiple myeloma.
Conclusions:
- Hsp90 inhibitors represent a promising therapeutic class for cancer treatment due to their multi-targeted approach.
- Further development of Hsp90 inhibitors with improved properties is underway.
- Hsp90 inhibitors are expected to play an increasingly significant role in clinical oncology.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...